Clinical trial
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
NCT00417287 · Cascadian Therapeutics Inc., Industry · Terminated
Key facts
| NCT number | NCT00417287 |
|---|---|
| Title | Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer |
| Official title | A Randomized Phase II Open-Label Study of Two Different Dose Levels of PX-12 in Patients With Advanced Carcinoma of the Pancreas Whose Tumors Have Progressed on Gemcitabine or on a Gemcitabine-Containing Combination |
| Lead sponsor | Cascadian Therapeutics Inc., Industry |
| Collaborators | National Cancer Institute (NCI) NIH Translational Genomics Research Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | PX-12 |
| Enrollment | 17 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 1, 2007 |
| Last update posted | May 16, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: